ITC Launches 337 Case Over Lilly's Gemzar Patent

Law360, New York (March 17, 2011, 5:29 PM EDT) -- The U.S. International Trade Commission on Thursday launched an investigation to determine if Hospira Inc. and affiliated pharmaceutical suppliers are importing generic versions of Eli Lilly & Co.’s cancer drug Gemzar.

The ITC announced that it is taking up Eli Lilly’s complaint and investigating whether Hospira, Intas Pharmaceuticals Ltd., Jiangsu Hansoh Pharmaceutical Co. Ltd. and ChemWerth Inc. are importing or selling gemcitabine products that allegedly infringe U.S. Patent Number 5,606,048.

Lilly filed suit at the ITC in January alleging that the respondents violate section 337 of...
To view the full article, register now.